Patrizia Ricci
Avellino, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Complement Biomarkers for Monitoring Last-Generation Complement Inhibitors in Paroxysmal Nocturnal Hemoglobinuria Patients.
Journal: American journal of hematology
Published: November 14, 2025
The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab.
Journal: British journal of haematology
Published: October 31, 2022
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Journal: Frontiers in immunology
Published: March 16, 2019
Eltrombopag for post-transplant cytopenias due to poor graft function.
Journal: Bone marrow transplantation
Published: August 09, 2018
Acute immune toxicity during anti-thymocyte globulin: That's CARPA!
Journal: American journal of hematology
Published: October 04, 2017
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
Journal: Journal of hematology & oncology
Published: April 10, 2017
Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria.
Journal: Blood
Published: February 02, 2015
Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells.
Journal: Journal of cellular and molecular medicine
Published: December 22, 2014
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.
Journal: Blood
Published: February 06, 2014
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
Journal: Haematologica
Published: September 17, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026